Results 81 to 90 of about 38,408 (255)

The Role of Magnetic Resonance Spectroscopy (MRS), Diffusion‐Tensor‐Imaging (DTI) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review

Journal of Magnetic Resonance Imaging, Volume 63, Issue 6, Page 1509-1545, June 2026.
ABSTRACT Alzheimer's disease (AD) is one of the most common neurological disorders affecting older adults, with approximately 7.2 million cases only in the United States. This number is projected to increase to 13.8 million in the United States by 2060, leading to increased expenditures for healthcare, long‐term care and hospice services. Consequently,
Valentina Zecca, Gianmauro Palombelli, Nicola Vanacore, Rossella Canese   +3 more
wiley   +1 more source

Beneficial effects of pharmacological treatment in post-stroke dynamic aphasia: a behavioural and neuroimaging study [PDF]

, 2018
Introduction : Dynamic Aphasia (DA) is a rare form of language disorder characterized by reduced spontaneous speech with preservation of other language functions.
Beltrán-Corbellini, Álvaro, Berthier-Torres, Marcelo Luis, Davila, Guadalupe, Edelkraut, Lisa-Marie, López-Barroso, Diana, Paredes-Pacheco, José, Reina, Sergio, Roé-Vellvé, Núria, Torres-Prioris, María José   +8 more
core  

Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease [PDF]

, 2013
This review describes the preclinical mechanisms that may underlie the increased therapeutic benefit of combination therapy—with the N-methyl-d-aspartate receptor antagonist, memantine, and an acetylcholinesterase inhibitor (AChEI)—for the treatment of ...
Andrzej Dekundy, Chris G. Parsons, Irena Pulte, Wojciech Danysz   +3 more
core   +1 more source

Pharmacodynamics of Memantine: An Update [PDF]

Current Neuropharmacology, 2008
Memantine received marketing authorization from the European Agency for the Evaluation of Medicinal Products (EMEA) for the treatment of moderately severe to severe Alzheimer s disease (AD) in Europe on 17(th) May 2002 and shortly thereafter was also approved by the FDA for use in the same indication in the USA.
Rammes, G., Danysz, W., Parsons, C.
openaire   +3 more sources

Memantine as an Adjunctive Treatment for Residual Anxiety and Agitation in Early Parkinson's Disease With Depression: A Case Report

Neuropsychopharmacology Reports, Volume 46, Issue 2, June 2026.
Low‐dose memantine was associated with rapid improvement of residual anxiety and agitation in an early‐stage Parkinson's disease patient without dementia, after only partial response to antidepressant treatment. This case highlights NMDA receptor modulation as a potential adjunctive approach for non‐motor psychiatric symptoms in Parkinson's disease ...
Takaumi Haga, Yuhei Mori, Nozomu Matsuda, Aya Sato, Yuhei Suzuki, Jiro Ono, Itaru Miura   +6 more
wiley   +1 more source

Combined Inhibition of TRPM4/NMDA Receptor Complex and Extrasynaptic NMDA Receptors Is Candidate Therapeutic Target for Suppression of Epileptic Seizures and Improvement of Cognitive Impairments

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Cognitive impairments are important therapeutic targets in epilepsy medication; however, effective pharmacological treatments for epilepsy patients with comorbid cognitive impairment have not been established. Effects of chronic administration of MK‐801 (noncompetitive NMDA receptor inhibitor), memantine (low‐affinity extrasynaptic‐NMDA ...
Motohiro Okada, Ruri Okubo, Tomoka Oka, Eishi Motomura   +3 more
wiley   +1 more source

Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids. [PDF]

, 2019
Tramadol is one of the most commonly used analgesics worldwide, classified as having a low abuse potential by U.S. Drug Enforcement Agency, and often recommended in pain management guidelines.
Abagyan, Ruben, Atayee, Rabia S, Makunts, Tigran, U, Andrew   +3 more
core   +1 more source

Memantine prevents cardiomyocytes nuclear size reduction in the left ventricle of rats exposed to cold stress [PDF]

, 2009
OBJECTIVES: Memantine is an N-methyl-d-aspartate (NMDA) glutamate receptor antagonist used to treat Alzheimer's disease. Previous studies have suggested that receptor blockers act as neuroprotective agents; however, no study has specifically investigated
ABREU, Luiz Carlos de, F. FILHO, Celso, FERREIRA, Celso, FERREIRA, Marcelo, MENEGHINI, Adriano, MURAD, Neif, VALENTI, Vitor E.   +6 more
core   +6 more sources

The Recruitment and Retention of Individuals With Intellectual Disability in Randomized Controlled Trials: A Scoping Review

British Journal of Learning Disabilities, Volume 54, Issue 2, Page 171-211, June 2026.
ABSTRACT Background People with intellectual disabilities face significant health disparities and often encounter barriers in accessing healthcare services. Although research supports the need for reasonable adjustments to improve healthcare access for this population, implementation in acute healthcare settings remains limited.
Owen Doody, Louise Murphy, Ruth Ryan, Rosemary Lyons, Wenyi Tang, Lorna Bourke   +5 more
wiley   +1 more source

The Concentration of Memantine in the Cerebrospinal Fluid of Alzheimer’s Disease Patients and Its Consequence to Oxidative Stress Biomarkers

Frontiers in Pharmacology, 2019
Memantine is a noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist utilized as a palliative cure for Alzheimer’s disease. This is the second study examining the memantine concentrations in cerebrospinal fluid.
Martin Valis, David Herman, David Herman, Nela Vanova, Nela Vanova, Jiri Masopust, Jiri Masopust, Oldrich Vysata, Jakub Hort, Jakub Hort, Zbysek Pavelek, Blanka Klimova, Kamil Kuca, Jan Misik, Jan Misik, Jana Zdarova Karasova, Jana Zdarova Karasova   +16 more
doaj   +1 more source